Efficacy and Safety of SPA100 (Fixed-dose Combination of Aliskiren/Amlodipine) in Patients With Essential Hypertension

This study has been completed.

Sponsor:

Information provided by (Responsible Party):

Novartis

ClinicalTrials.gov Identifier:

NCT01237223

First received: October 29, 2010

Last updated: May 11, 2012

Last verified: May 2012

History of Changes

Results First Received: May 11, 2012

Study Type:	Interventional
Study Design:	Allocation: Randomized; Intervention Model: Factorial Assignment; Masking: Double Blind (Subject, Outcomes Assessor); Primary Purpose: Treatment
Condition:	Essential Hypertension
Interventions:	Drug: Aliskiren/Amlodipine 150/2.5 mg Drug: Aliskiren/amlodipine 150/5 mg Drug: Aliskiren 150 mg Drug: Amlodipine 2.5 mg Drug: Placebo of Aliskiren Drug: Placebo of Amlodipine Drug: Placebo of Aliskiren/amlodipine 150/2.5 mg Drug: Placebo of Aliskiren/amlodipine 150/5 mg

Participant Flow

Show Participant Flow

Baseline Characteristics

Hide Baseline Characteristics

Reporting Groups

	Description
Placebo	In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study. Patients were received matching placebo of aliskiren/amlodipine 150/5 mg tablet, aliskiren/amlodipine 150/2.5 mg tablet, aliskiren 150 mg tablet and two amlodipine 2.5 mg capsules once daily for 8 weeks of double blind period.
Aliskiren 150 mg	In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study. Patients received Aliskiren 150 mg tablet once daily (o.d)+ placebo of two amlodipine 2.5 mg capsule o.d., aliskiren/amlodipine 150/5 mg tablet o.d , aliskiren/amlodipine 150/2.5 mg tablet o.d for 8 weeks of double blind period.
Amlodipine 2.5 mg	In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study. Patients received Amlodipine 2.5 mg capsule once daily (o.d)+ placebo of amlodipine 2.5 mg capsule o.d., Aliskiren 150 mg o.d., aliskiren/amlodipine 150/5 mg tablet o.d , aliskiren/amlodipine 150/2.5 mg tablet o.d for 8 weeks of double blind period.
Amlodipine 5 mg	In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study. Patients received amlodipine 5 mg (two amlodipine 2.5 mg capsules o.d.)+ placebo of aliskiren 150 mg tablet o.d., aliskiren/amlodipine 150/5 mg tablet o.d. , aliskiren/amlodipine 150/2.5 mg tablet o.d. for 8 weeks of double blind period.
Aliskiren/Amlodipine 150/2.5 mg	In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study. Patients received aliskiren/amlodipine 150/2.5 mg tablet o.d. + placebo of two amlodipine 2.5 mg capsules o.d., aliskiren 150 mg tablet o.d., aliskiren/amlodipine 150/5 mg tablet o.d. for 8 weeks of double blind period.
Aliskiren/Amlodipine 150/5 mg	In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study. Patients received aliskiren/amlodipine 150/5 mg tablet o.d. + placebo of two amlodipine 2.5 mg capsules o.d., aliskiren 150 mg tablet o.d., aliskiren/amlodipine 150/2.5 mg tablet o.d. for 8 weeks of double blind period.
Total	Total of all reporting groups

Baseline Measures

	Placebo	Aliskiren 150 mg	Amlodipine 2.5 mg	Amlodipine 5 mg	Aliskiren/Amlodipine 150/2.5 mg	Aliskiren/Amlodipine 150/5 mg	Total
Number of Participants [units: participants]	153	157	158	158	159	159	944
Age ^[1] [units: years] Mean ± Standard Deviation	54.6 ± 8.35	55.0 ± 9.96	54.8 ± 10.25	55.8 ± 10.05	54.6 ± 11.11	55.5 ± 9.86	55.1 ± 9.96
Age, Customized [units: participants]
< 65 years	128	131	129	126	125	127	766
>=65 years	25	26	29	32	34	32	178
Gender [units: participants]
Female	45	39	45	51	51	57	288
Male	108	118	113	107	108	102	656

[1]	Baseline measurements were based on randomized patients.

Outcome Measures

Show All Outcome Measures

1. Primary:

Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP) to End of Study (Week 8) [ Time Frame: Baseline, Week 8 ]

Show Outcome Measure 1

2. Secondary:

Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) to End of Study (Week 8) [ Time Frame: Baseline, Week 8 ]

Show Outcome Measure 2

3. Secondary:

Percentage of Participants Achieving Blood Pressure Control at Endpoint [ Time Frame: 8 weeks ]

Show Outcome Measure 3

4. Secondary:

Percentage of Participants Achieving a Successful Response Rate [ Time Frame: 8 weeks ]

Show Outcome Measure 4

5. Secondary:

Number of Participants With Adverse Events, Serious Adverse Events and Death [ Time Frame: 8 weeks ]

Show Outcome Measure 5

Serious Adverse Events

Show Serious Adverse Events

Other Adverse Events

Show Other Adverse Events

More Information

Hide More Information

Certain Agreements:

Principal Investigators are NOT employed by the organization sponsoring the study.

There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

The agreement is:

	The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
	The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
	Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed. Restriction Description: The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.

Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

Results Point of Contact:

Name/Title: Study Director
Organization: Novartis Pharmaceuticals
phone: 862-778-8300

No publications provided

Responsible Party:	Novartis
ClinicalTrials.gov Identifier:	NCT01237223 History of Changes
Other Study ID Numbers:	CSPA100A1301
Study First Received:	October 29, 2010
Results First Received:	May 11, 2012
Last Updated:	May 11, 2012
Health Authority:	Japan: Pharmaceuticals and Medical Devices Agency

To Top